Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 7
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 evolution during treatment of chronic infection.
Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, Roberts DJ, Chandra A, Temperton N; CITIID-NIHR BioResource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium; Sharrocks K, Blane E, Modis Y, Leigh KE, Briggs JAG, van Gils MJ, Smith KGC, Bradley JR, Smith C, Doffinger R, Ceron-Gutierrez L, Barcenas-Morales G, Pollock DD, Goldstein RA, Smielewska A, Skittrall JP, Gouliouris T, Goodfellow IG, Gkrania-Klotsas E, Illingworth CJR, McCoy LE, Gupta RK. Kemp SA, et al. Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5. Nature. 2021. PMID: 33545711 Free PMC article.
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for virus infection through the engagement of the human ACE2 protein(1) and is a major antibody target. ...The spike deleti …
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 …
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study.
Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, Drew DA, Nguyen LH, Polidori L, Selvachandran S, Hu C, Capdevila J; COVID-19 Genomics UK (COG-UK) Consortium; Hammers A, Chan AT, Wolf J, Spector TD, Steves CJ, Ourselin S. Graham MS, et al. Lancet Public Health. 2021 May;6(5):e335-e345. doi: 10.1016/S2468-2667(21)00055-4. Epub 2021 Apr 12. Lancet Public Health. 2021. PMID: 33857453 Free PMC article.
BACKGROUND: The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in England. ...From this dataset, we also estimated the frequency of possible reinfection, defined as the presence of two reported positive tests separated by more than 90 days …
BACKGROUND: The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in England. ...From this dataset, we …
Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort.
Handy A, Banerjee A, Wood AM, Dale C, Sudlow CLM, Tomlinson C, Bean D, Thygesen JH, Mizani MA, Katsoulis M, Takhar R, Hollings S, Denaxas S, Walker V, Dobson R, Sofat R; CVD-COVID-UK Consortium. Handy A, et al. Heart. 2022 May 25;108(12):923-931. doi: 10.1136/heartjnl-2021-320325. Heart. 2022. PMID: 35273122 Free PMC article.
RESULTS: From 972 971 individuals with AF (age 79 (9.3), female 46.2%) and CHA(2)DS(2)-VASc score 2, 88.0% (n=856 336) had pre-existing AT use, 3.8% (n=37 418) had a COVID-19 hospitalisation and 2.2% (n=21 116) died, followed up to 1 May 2021. ...CONCLUSIONS: Pre-ex …
RESULTS: From 972 971 individuals with AF (age 79 (9.3), female 46.2%) and CHA(2)DS(2)-VASc score 2, 88.0% (n=856 336) had pre-existing AT u …
Detecting SARS-CoV-2 variants with SNP genotyping.
Harper H, Burridge A, Winfield M, Finn A, Davidson A, Matthews D, Hutchings S, Vipond B, Jain N; COVID-19 Genomics UK (COG-UK) Consortium; Edwards K, Barker G. Harper H, et al. PLoS One. 2021 Feb 24;16(2):e0243185. doi: 10.1371/journal.pone.0243185. eCollection 2021. PLoS One. 2021. PMID: 33626040 Free PMC article.
Genotyping is a rapid, high-throughput and low-cost alternative for screening positive SARS-CoV-2 samples in many settings. We have designed a SNP identification pipeline to identify genetic variation using sequenced SARS-CoV-2 samples. . …
Genotyping is a rapid, high-throughput and low-cost alternative for screening positive SARS-CoV-2 samples in many setti …
Patterns of within-host genetic diversity in SARS-CoV-2.
Tonkin-Hill G, Martincorena I, Amato R, Lawson ARJ, Gerstung M, Johnston I, Jackson DK, Park N, Lensing SV, Quail MA, Gonçalves S, Ariani C, Spencer Chapman M, Hamilton WL, Meredith LW, Hall G, Jahun AS, Chaudhry Y, Hosmillo M, Pinckert ML, Georgana I, Yakovleva A, Caller LG, Caddy SL, Feltwell T, Khokhar FA, Houldcroft CJ, Curran MD, Parmar S; COVID-19 Genomics UK (COG-UK) Consortium; Alderton A, Nelson R, Harrison EM, Sillitoe J, Bentley SD, Barrett JC, Torok ME, Goodfellow IG, Langford C, Kwiatkowski D; Wellcome Sanger Institute COVID-19 Surveillance Team. Tonkin-Hill G, et al. Elife. 2021 Aug 13;10:e66857. doi: 10.7554/eLife.66857. Elife. 2021. PMID: 34387545 Free PMC article.
Monitoring the spread of SARS-CoV-2 and reconstructing transmission chains has become a major public health focus for many governments around the world. ...Could genetic testing of within-host variants shed light on factors driving SARS-CoV-2 …
Monitoring the spread of SARS-CoV-2 and reconstructing transmission chains has become a major public health focus for m …
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O'Toole Á, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman NJ, McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N, Sillitoe J, Kwiatkowski DP; COVID-19 Genomics UK (COG-UK) consortium; Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, Ferguson NM. Volz E, et al. Nature. 2021 May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x. Epub 2021 Mar 25. Nature. 2021. PMID: 33767447 Free article.
The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public Health England(1), was first identified in the UK in late summer to early autumn 2020(2). Whole-genome SARS-CoV-2 sequence data collecte …
The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public Health England(1), was first id …
COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study.
Kläser K, Molteni E, Graham M, Canas LS, Österdahl MF, Antonelli M, Chen L, Deng J, Murray B, Kerfoot E, Wolf J, May A, Fox B, Capdevila J; COVID-19 Genomics U. K. (COG-UK) Consortium; Modat M, Hammers A, Spector TD, Steves CJ, Sudre CH, Ourselin S, Duncan EL. Kläser K, et al. Sci Rep. 2022 Jun 28;12(1):10904. doi: 10.1038/s41598-022-14016-0. Sci Rep. 2022. PMID: 35764879 Free PMC article.
The Delta (B.1.617.2) variant was the predominant UK circulating SARS-CoV-2 strain between May and December 2021. ...This prospective observational cohort study assessed symptomatic adults participating in the app-based COVID Symptom Study who tested p …
The Delta (B.1.617.2) variant was the predominant UK circulating SARS-CoV-2 strain between May and December 2021 …
COVID-19 risk mitigation in reopening mass cultural events: population-based observational study for the UK Events Research Programme in Liverpool City Region.
Burnside G, Cheyne CP, Leeming G, Humann M, Darby A, Green MA, Crozier A, Maskell S, O'Halloran K, Musi E, Carmi E, Khan N, Fisher D, Corcoran R, Dunning J, Edmunds WJ, Tharmaratnam K, Hughes DM, Malki-Epshtein L, Cook M, Roberts BM, Gallagher E, Howell K, Chand M, Kemp R, Boulter M, Fowler T, Semple MG, Coffey E, Ashton M; COVID-19 Genomics UK (COG-UK) Consortium; García-Fiñana M, Buchan IE. Burnside G, et al. J R Soc Med. 2024 Jan;117(1):11-23. doi: 10.1177/01410768231182389. Epub 2023 Jun 23. J R Soc Med. 2024. PMID: 37351911 Free PMC article.
OBJECTIVES: To understand severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission risks, perceived risks and the feasibility of risk mitigations from experimental mass cultural events before coron …
OBJECTIVES: To understand severe acute respiratory syndrome coronavirus 2 (SARS-CoV- …
The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis.
Pascall DJ, Vink E, Blacow R, Bulteel N, Campbell A, Campbell R, Clifford S, Davis C, da Silva Filipe A, El Sakka N, Fjodorova L, Forrest R, Goldstein E, Gunson R, Haughney J, Holden MTG, Honour P, Hughes J, James E, Lewis T, Lycett S, MacLean O, McHugh M, Mollett G, Onishi Y, Parcell B, Ray S, Robertson DL, Shabaan S, Shepherd JG, Smollett K, Templeton K, Wastnedge E, Wilkie C, Williams T, Thomson EC; COVID-19 Genomics UK (COG-UK) Consortium. Pascall DJ, et al. PLoS One. 2023 Apr 13;18(4):e0284187. doi: 10.1371/journal.pone.0284187. eCollection 2023. PLoS One. 2023. PMID: 37053201 Free PMC article.
OBJECTIVES: The SARS-CoV-2 Alpha variant was associated with increased transmission relative to other variants present at the time of its emergence and several studies have shown an association between Alpha variant infection and increased hospitalisation and …
OBJECTIVES: The SARS-CoV-2 Alpha variant was associated with increased transmission relative to other variants present …
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.
Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, Lytras S, Czudnochowski N, Shah R, Meury M, Jesudason N, De Marco A, Li K, Bassi J, O'Toole A, Pinto D, Colquhoun RM, Culap K, Jackson B, Zatta F, Rambaut A, Jaconi S, Sreenu VB, Nix J, Zhang I, Jarrett RF, Glass WG, Beltramello M, Nomikou K, Pizzuto M, Tong L, Cameroni E, Croll TI, Johnson N, Di Iulio J, Wickenhagen A, Ceschi A, Harbison AM, Mair D, Ferrari P, Smollett K, Sallusto F, Carmichael S, Garzoni C, Nichols J, Galli M, Hughes J, Riva A, Ho A, Schiuma M, Semple MG, Openshaw PJM, Fadda E, Baillie JK, Chodera JD; ISARIC4C Investigators; COVID-19 Genomics UK (COG-UK) Consortium; Rihn SJ, Lycett SJ, Virgin HW, Telenti A, Corti D, Robertson DL, Snell G. Thomson EC, et al. Cell. 2021 Mar 4;184(5):1171-1187.e20. doi: 10.1016/j.cell.2021.01.037. Epub 2021 Jan 28. Cell. 2021. PMID: 33621484 Free PMC article.
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. ...Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlig …
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics …
12 results